In MPN, chronic administration of β3-adrenergic agonists to compensate for the defective innervation can rescue Nestin+ niche cells and improve myelofibrosis (BM scarring hampering normal hematopoiesis) in both mice86 and humans87. Here, NES is linked to myeloproliferative disorder.